246 related articles for article (PubMed ID: 33352387)
1. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.
Zhao T; Meng Q; Kang D; Ji J; De Clercq E; Pannecouque C; Liu X; Zhan P
Eur J Med Chem; 2019 Nov; 182():111619. PubMed ID: 31434039
[TBL] [Abstract][Full Text] [Related]
3. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates.
Samuele A; Bisi S; Kataropoulou A; La Regina G; Piscitelli F; Gatti V; Silvestri R; Maga G
Antivir Chem Chemother; 2011 Nov; 22(3):107-18. PubMed ID: 22095519
[TBL] [Abstract][Full Text] [Related]
5. New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
Nalli M; Armijos Rivera JI; Masci D; Coluccia A; Badia R; Riveira-Muñoz E; Brambilla A; Cinquina E; Turriziani O; Falasca F; Catalano M; Limatola C; Esté JA; Maga G; Silvestri R; Crespan E; La Regina G
Eur J Med Chem; 2020 Dec; 208():112696. PubMed ID: 32883642
[TBL] [Abstract][Full Text] [Related]
6. New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
Famiglini V; La Regina G; Coluccia A; Pelliccia S; Brancale A; Maga G; Crespan E; Badia R; Clotet B; Esté JA; Cirilli R; Novellino E; Silvestri R
Eur J Med Chem; 2014 Jun; 80():101-11. PubMed ID: 24769348
[TBL] [Abstract][Full Text] [Related]
7. Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
La Regina G; Coluccia A; Brancale A; Piscitelli F; Gatti V; Maga G; Samuele A; Pannecouque C; Schols D; Balzarini J; Novellino E; Silvestri R
J Med Chem; 2011 Mar; 54(6):1587-98. PubMed ID: 21366296
[TBL] [Abstract][Full Text] [Related]
8. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
Regina GL; Coluccia A; Piscitelli F; Bergamini A; Sinistro A; Cavazza A; Maga G; Samuele A; Zanoli S; Novellino E; Artico M; Silvestri R
J Med Chem; 2007 Oct; 50(20):5034-8. PubMed ID: 17803291
[TBL] [Abstract][Full Text] [Related]
9. Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.
Xu S; Song S; Sun L; Gao P; Gao S; Ma Y; Kang D; Cheng Y; Zhang X; Cherukupalli S; De Clercq E; Pannecouque C; Liu X; Zhan P
Bioorg Med Chem; 2022 Jan; 53():116531. PubMed ID: 34890994
[TBL] [Abstract][Full Text] [Related]
10. Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
Dousson C; Alexandre FR; Amador A; Bonaric S; Bot S; Caillet C; Convard T; da Costa D; Lioure MP; Roland A; Rosinovsky E; Maldonado S; Parsy C; Trochet C; Storer R; Stewart A; Wang J; Mayes BA; Musiu C; Poddesu B; Vargiu L; Liuzzi M; Moussa A; Jakubik J; Hubbard L; Seifer M; Standring D
J Med Chem; 2016 Mar; 59(5):1891-8. PubMed ID: 26804933
[TBL] [Abstract][Full Text] [Related]
11. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
Silvestri R; Artico M; De Martino G; La Regina G; Loddo R; La Colla M; Mura M; La Colla P
J Med Chem; 2004 Jul; 47(15):3892-6. PubMed ID: 15239667
[TBL] [Abstract][Full Text] [Related]
12. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
13. New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Brancale A; Piscitelli F; Famiglini V; Cosconati S; Maga G; Samuele A; Gonzalez E; Clotet B; Schols D; Esté JA; Novellino E; Silvestri R
J Med Chem; 2012 Jul; 55(14):6634-8. PubMed ID: 22712652
[TBL] [Abstract][Full Text] [Related]
14. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
Huang B; Li C; Chen W; Liu T; Yu M; Fu L; Sun Y; Liu H; De Clercq E; Pannecouque C; Balzarini J; Zhan P; Liu X
Eur J Med Chem; 2015 Mar; 92():754-65. PubMed ID: 25626145
[TBL] [Abstract][Full Text] [Related]
15. Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography.
Chan AH; Lee WG; Spasov KA; Cisneros JA; Kudalkar SN; Petrova ZO; Buckingham AB; Anderson KS; Jorgensen WL
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9725-9730. PubMed ID: 28827354
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided design of novel biphenyl-quinazoline derivatives as potent non-nucleoside reverse transcriptase inhibitors featuring improved anti-resistance, selectivity, and solubility.
Wang JS; Zhao KX; Zhang K; Pannecouque C; De Clercq E; Wang S; Chen FE
Bioorg Chem; 2024 Jun; 147():107340. PubMed ID: 38593532
[TBL] [Abstract][Full Text] [Related]
17. 1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
Novikov MS; Ivanova ON; Ivanov AV; Ozerov AA; Valuev-Elliston VT; Temburnikar K; Gurskaya GV; Kochetkov SN; Pannecouque C; Balzarini J; Seley-Radtke KL
Bioorg Med Chem; 2011 Oct; 19(19):5794-802. PubMed ID: 21903401
[TBL] [Abstract][Full Text] [Related]
18. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
Frey KM; Puleo DE; Spasov KA; Bollini M; Jorgensen WL; Anderson KS
J Med Chem; 2015 Mar; 58(6):2737-45. PubMed ID: 25700160
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
[TBL] [Abstract][Full Text] [Related]
20. Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
Famiglini V; Silvestri R
Antivir Chem Chemother; 2018; 26():2040206617753443. PubMed ID: 29417826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
